4//SEC Filing
Ring Christine 4
Accession 0001817199-25-000007
CIK 0001549595other
Filed
Nov 23, 7:00 PM ET
Accepted
Nov 24, 6:06 PM ET
Size
9.0 KB
Accession
0001817199-25-000007
Insider Transaction Report
Form 4
Ring Christine
Chief Legal Officer
Transactions
- Sale
Common Stock
2025-11-24$17.07/sh−37,600$641,697→ 50,897 total - Exercise/Conversion
Common Stock
2025-11-24$1.86/sh+37,600$69,936→ 88,497 total - Exercise/Conversion
Employee Stock Option (right to buy)
2025-11-24−37,600→ 16,163 totalExercise: $1.86Exp: 2029-09-30→ Common Stock (37,600 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- [F2]Represents the weighted average sale price. The lowest price at which shares were sold was $17.00 and the highest price at which shares were sold was $17.26. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- [F3]The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.
Documents
Issuer
Nurix Therapeutics, Inc.
CIK 0001549595
Entity typeother
Related Parties
1- filerCIK 0001817199
Filing Metadata
- Form type
- 4
- Filed
- Nov 23, 7:00 PM ET
- Accepted
- Nov 24, 6:06 PM ET
- Size
- 9.0 KB